BioCentury | Jan 13, 2021

Boehringer accesses untouched cancer targets through Enara deal

Boehringer’s reach into the most cutting-edge science continues through its new deal with Enara to access dark antigen targets for cancer immunotherapies.  Boehringer Ingelheim GmbH teamed up with...
BioCentury | Jan 12, 2021

Seeking to fill gap in the clinic, LSP raises €50M toward dementia-focused fund

European investment firm LSP has launched a new dementia-focused fund to fill what it believes is a gap in support for development-stage companies evaluating treatments for neurodegenerative diseases. The firm has named Philip Scheltens, who...
BioCentury | Jan 9, 2021

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Jan 8, 2021

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

Carlyle leads Abbisko’s $123M series DShanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company named Warburg Pincus, OrbiMed, Lake Bleu Capital and an...
BioCentury | Dec 3, 2020

Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality

Artios’ deal with German pharma Merck represents the latest vote of confidence in the DNA damage repair sector, and extends the privately held biotech’s cash runway as it prepares for its first clinical trials. For its...
BioCentury | Nov 23, 2020
Emerging Company Profile

SV Health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

Catamaran debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR NK cell therapies that seed investor SV Health hopes can “democratize access to cell therapy.”  SV’s Houman Ashrafian...
BioCentury | Nov 10, 2020
Politics, Policy & Law

Bingham’s tenure with U.K. COVID vaccine task force drawing to a close

Kate Bingham will step down, as planned, as chair of the U.K. Vaccine Taskforce in the coming weeks. Bingham joined the COVID-focused task force in May shortly after its launch with a commitment to...
BioCentury | Sep 16, 2020

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

NIH launches Accelerating Medicines Partnership for schizophreniaNIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative...
BioCentury | Sep 11, 2020
Product Development

Governments must work alongside industry to fill the cracks exposed by COVID-19 before the next, inevitable, pandemic

This is the fifth and final article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

This is the fourth article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
Items per page:
1 - 10 of 531